John Doux
Direktor/Vorstandsmitglied bei Lutris Pharma Ltd.
Profil
John Doux is currently a Director at Palvella Therapeutics, Inc. and Lutris Pharma Ltd.
He previously worked as an Analyst at Palo Alto Investors LP.
Before that, he was a Director at Brickell Subsidiary, Inc. and ACELYRIN, Inc. Dr. Doux received his undergraduate and doctorate degrees from Stanford University and his MBA from The Wharton School of the University of Pennsylvania.
Aktive Positionen von John Doux
Unternehmen | Position | Beginn |
---|---|---|
Palo Alto Investors LP
Palo Alto Investors LP Investment ManagersFinance Palo Alto Investors LLC (PAI) is a registered investment advisor and hedge fund manager headquartered in Palo Alto, California. The firm was founded by William L. Edwards in 1989 as Palo Alto Investors LLC and converted into a California limited partnership in 2018. They are a subsidiary of PAI LLC. PAI serves as the investment adviser to private pooled investment vehicles, the securities of which are offered to investors on a private placement basis. | Analyst-Equity | 01.01.2004 |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Direktor/Vorstandsmitglied | - |
Lutris Pharma Ltd.
Lutris Pharma Ltd. Pharmaceuticals: MajorHealth Technology Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von John Doux
Unternehmen | Position | Ende |
---|---|---|
ACELYRIN, INC. | Direktor/Vorstandsmitglied | - |
Brickell Subsidiary, Inc.
Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Direktor/Vorstandsmitglied | - |
Ausbildung von John Doux
Stanford University | Doctorate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ACELYRIN, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Palo Alto Investors LP
Palo Alto Investors LP Investment ManagersFinance Palo Alto Investors LLC (PAI) is a registered investment advisor and hedge fund manager headquartered in Palo Alto, California. The firm was founded by William L. Edwards in 1989 as Palo Alto Investors LLC and converted into a California limited partnership in 2018. They are a subsidiary of PAI LLC. PAI serves as the investment adviser to private pooled investment vehicles, the securities of which are offered to investors on a private placement basis. | Finance |
Brickell Subsidiary, Inc.
Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Health Technology |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Health Technology |
Lutris Pharma Ltd.
Lutris Pharma Ltd. Pharmaceuticals: MajorHealth Technology Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel. | Health Technology |